Accessibility Menu
Astellas Pharma logo

Astellas Pharma(OTC) ALPMY

Market Cap$27.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+107%
5 Year+5%
1 Year+42%
1 Month+11%
$15.47
+2.32%
+0.35Today
Astellas Pharma last closing stock price
MetricPriceDate
Last closeUSD 15.122026-09-02
Astellas Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.67%USD 15.022026-08-26
1 month+10.61%USD 13.672026-08-03
3 month+11.67%USD 13.542026-06-04
Year to date+15.51%USD 13.092025-12-31
1 year+41.73%USD 10.672025-09-02
3 year+12.81%USD 13.402023-09-01
5 year+4.5%USD 14.472021-09-03
Since inception+106.85%USD 7.312008-12-12

Astellas Pharma Financials at a Glance

Market Cap

$27.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.41T

Net Income (TTM)

¥384.24B

EPS (TTM)

$1.31

P/E Ratio

11.50

Dividend

$0.50

Beta (Volatility)

0.31 (Low)

Price

$15.47

Volume

78,025

Open

$15.52

Previous Close

$15.47

Daily Range

$15.32 - $16.01

52-Week Range

$10.03 - $17.35

Estimated Earnings Date

Oct 29, 2026

ALPMY News

MandA Deal

Why It's So Dang Hard to Value Biotech Deals

Brian Orelli, PhDMar 21, 2018
pfizer via facebook2

What Pfizer Gets in Its $14 Billion Medivation Deal

Todd CampbellAug 23, 2016
money inside pills flickr user chris potter

What Sent Medivation, Inc.'s Shares Soaring 25.1% In April

Todd CampbellMay 3, 2016
mdvn pipe

Sanofi's Bid for Medivation Is Too Low

Todd CampbellApr 28, 2016
johnsonandjohnson2

J&J's Q1 Results Suggest More Upside for Medivation, Inc.

Todd CampbellApr 27, 2016
bernie top

How Biotech Is Getting Berned by Sanders

Todd CampbellMar 31, 2016
take long view

Why Medivation Shares Are Tanking Today

Todd CampbellMar 29, 2016
Image by stevepb via pixabay copy 2

Medivation Inc. Stock Is Rising Today -- Here's Why

Brian FeroldiFeb 26, 2016
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company addresses critical unmet medical needs across various therapeutic areas, including oncology and urology.

Products and Services
  • Oncology treatments like XTANDI and PADCEV
  • Urological products including Betanis and Vesicare
  • Immunosuppressants such as Prograf and Evrenzo for chronic kidney disease
Growth Outlook
  • Strong pipeline with multiple strategic collaborations enhancing innovation
  • Recent partnerships with Merck & Co. and Harvard University for advanced research
  • Focus on expanding therapeutic areas, including targeted radiotherapies
Financial Highlights
  • Recent quarterly revenue of 649.35 billion JPY, showing consistent growth
  • Net income margin of 22.1% in the latest quarter, indicating strong profitability
  • TTM P/E ratio of 11.72, suggesting potential value for investors
Astellas Pharma Inc. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that addresses significant health challenges. The company's commitment to innovation is evident through its strategic partnerships and ongoing research initiatives. Recent financial performance highlights a robust revenue stream and strong profitability, making it an attractive option for potential investors looking for growth in the healthcare sector.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, TY 103-8411, JP

ALPMY Financials

Key Financial Metrics (TTM)

Gross Margin

74.71%

Operating Margin

21.81%

Net Income Margin

16.04%

Return on Equity

20.41%

Return on Capital

21.33%

Return on Assets

9.88%

Earnings Yield

8.70%

Dividend Yield

3.28%

Payout Ratio

38.30%

Stock Overview

Market Cap

$27.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79B

Volume

78.03K

Avg. Volume

173.20K

Financials (TTM)

Gross Profit

¥1.77T

Operating Income

¥538.55B

EBITDA

¥531.90B

Operating Cash Flow

¥608.45B

Capital Expenditure

-¥58.42B

Free Cash Flow

¥550.03B

Cash & ST Invst.

¥243.08B

Total Debt

¥585.98B

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 11,210,593,310-2.8%
20242024-03-31JPY 11,104,729,504-0.9%
20252025-03-31JPY 12,543,905,53613.0%
20262026-03-31JPY 14,196,133,79713.2%
Astellas Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-305.5%
Q32025-12-319.0%
Q42026-03-3111.3%
Q12026-06-300.3%
Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.40-33.1%
20242024-03-31JPY 0.07-83.6%
20252025-03-31JPY 0.19182.3%
20262026-03-31JPY 1.08481.3%
Astellas Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3018.1%
Q32025-12-3126.4%
Q42026-03-31-42.7%
Q12026-06-30147.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥649.35B

+28.4%

Gross Profit

¥488.89B

+19.0%

Gross Margin

75.29%

N/A

Market Cap

$27.11BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.92M

N/A

Employees

14,099

N/A

Net Income

¥143.54B

+109.8%

EBITDA

¥238.73B

+57.2%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥243.08B

+12.9%

Total Debt

¥585.98B

-34.1%

Accounts Receivable

¥839.23B

+25.5%

Inventory

¥335.66B

+9.8%

Long Term Debt

¥317.89B

-43.0%

Short Term Debt

¥268.09B

-19.1%

Return on Assets

9.88%

N/A

Return on Invested Capital

20.18%

N/A

Free Cash Flow

¥76.00B

+80.8%

Operating Cash Flow

¥88.78B

+61.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WXXWYWuXi Biologics (Cayman) Inc.
$13.05+3.00%
ORINYOrion Oyj
$47.13+2.98%
WXIBFWuXi Biologics (Cayman) Inc.
$6.23+0.00%
GNMSFGenmab A/S
$338.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About ALPMY

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $15.47 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $10.03 and $17.35.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of ¥3.63B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported ¥1.51B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.28%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services